Jason Sheltzer (Cold Spring Harbor Laboratory) discusses challenges and best practices to generating gene knockouts in cell lines using CRISPR-Cas9, as well as his group’s tour de force application of the technology to reveal stunning discrepancies between drugs that are in clinical trials and their supposed mechanism of action.

CRISPR Functional Genomics Miniseries, Episode #6: Jason Sheltzer

Mary Ann Liebert, Inc. is a leading company in the Scientific, Technical, and Medical knowledge and information industry. We are known for authoritative international publications in cutting-edge basic and translational biomedical research, with expanding scope in engineering, business, environment, and legal publications. These publications play an active and important role in advancing critical research and facilitating collaboration throughout the world in academia, industry, and government, and are also highly respected resources for legislators, policy makers, and educators.

Share CRISPR Functional Genomics Miniseries, Episode #6: Jason Sheltzer

Sign up to save your podcasts

CRISPR Functional Genomics Miniseries, Episode #6: Jason Sheltzer

CRISPR Functional Genomics Miniseries, Episode #6: Jason Sheltzer